Health Care • Biotechnology: Commercial Physical & Biological Resarch
$120.39 ▲ +3.59
(+3.07%)
MKT CAP: $23.68B • VOL: 2.84M
52W L $89 52W H $133
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$101
MEDIAN
$135
MEAN
$137
HIGH
$164
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INCY TAPE
INCY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $145.67 | $138.45 | 2025-02-14 | $109.55 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $151.69 | $142.06 | 2025-02-06 | $113.17 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $137.24 | $132.43 | 2025-01-29 | $115.57 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $122.80 | — | 2025-01-17 | $117.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $105.94 | $114.37 | 2025-01-09 | $107.15 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $143.26 | $125.21 | 2024-12-18 | $104.74 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $116.78 | $121.59 | 2024-12-04 | $111.96 | -4.3% | 48% | C |